Ozaniak Andrej, Galova Dominika, Benesova Iva, Lischke Robert, Ozaniak Strizova Zuzana
Third Department of Surgery, First Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
J Thorac Dis. 2024 Oct 31;16(10):6863-6878. doi: 10.21037/jtd-24-472. Epub 2024 Oct 30.
Chest wall sarcomas are rare and pose significant technical challenges in surgical management, particularly in patients with advanced disease. In this study, we examined the extent of resection, reconstruction techniques, and oncological outcomes of patients with chest wall soft tissue and bone sarcomas.
This retrospective single-center series included patients who underwent surgery at our center between May 2014 and February 2022 for deep-seated/subfascial primary and recurrent soft tissue or bone sarcomas of the chest wall requiring significant resection and extensive reconstruction. We analyzed clinical and operative data, including extent of resection, reconstruction techniques, and oncological outcomes. Additionally, we compared survival outcomes between patients with primary and recurrent tumors, and examined how these were influenced by clinical factors using Cox proportional hazards regression analysis.
Of the 38 patients included, 22 were treated for primary or recurrent soft tissue sarcoma (STS) and 16 for bone sarcoma. microscopic radical resection (R0) was achieved in 95.45% and 93.75% of patients with soft tissue and bone sarcomas, respectively. Nonetheless, local recurrence or distant metastases occurred in 40%, 58.33%, and 40% of patients with primary soft tissue, recurrent soft tissue, and bone sarcomas, respectively. Adherence to clinical guidelines and treatment in the reference center was high for bone sarcoma (93.75%), but notably low for STS, resulting in 54.55% of these patients requiring re-resection. Compared with those who underwent only one surgery, patients who underwent re-resection had poorer postoperative outcomes, more severe complications, and longer hospital stay.
Chest wall sarcomas often require extensive resection and complex reconstruction. Although surgical treatment at reference sarcoma centers has significantly improved oncological and clinical outcomes, the prognosis of these patients remains guarded, necessitating further related research and continued refinement in surgical techniques, adjuvant therapies, and follow-up strategies.
胸壁肉瘤较为罕见,在手术治疗中面临重大技术挑战,尤其是对于晚期疾病患者。在本研究中,我们探讨了胸壁软组织和骨肉瘤患者的切除范围、重建技术及肿瘤学结局。
这项回顾性单中心研究纳入了2014年5月至2022年2月期间在本中心接受手术的患者,这些患者患有需要进行大面积切除和广泛重建的胸壁深部/筋膜下原发性及复发性软组织或骨肉瘤。我们分析了临床和手术数据,包括切除范围、重建技术及肿瘤学结局。此外,我们比较了原发性和复发性肿瘤患者的生存结局,并使用Cox比例风险回归分析研究了临床因素对这些结局的影响。
在纳入的38例患者中,22例接受原发性或复发性软组织肉瘤(STS)治疗,16例接受骨肉瘤治疗。软组织肉瘤和骨肉瘤患者分别有95.45%和93.75%实现了显微镜下根治性切除(R0)。然而,原发性软组织肉瘤、复发性软组织肉瘤和骨肉瘤患者分别有40%、58.33%和40%发生局部复发或远处转移。骨肉瘤患者对参考中心临床指南和治疗的依从性较高(93.75%),但STS患者的依从性显著较低,导致54.55%的此类患者需要再次切除。与仅接受一次手术的患者相比,接受再次切除的患者术后结局较差,并发症更严重,住院时间更长。
胸壁肉瘤通常需要广泛切除和复杂重建。尽管参考肉瘤中心的手术治疗显著改善了肿瘤学和临床结局,但这些患者的预后仍然不佳,需要进一步开展相关研究,并持续改进手术技术、辅助治疗和随访策略。